New Results in Depression Research pp 112-117 | Cite as
Treatment of Atypical Depression: Phenelzine, Imipramine, and Placebo
Abstract
The concept of atypical depression dates back to the late 1950s, when British investigators at St. Thomas’s Hospital in London attempted to characterize patients responding to the newly available antidepressant drug iproniazid. In an open clinical series, iproniazid, the first available monoamine oxidase inhibitor (MAOI), helped depressed patients who manifested prominent anxiety, hysterical features, phobic anxiety, emotional over-reactivity, assorted psychophysiological symptoms, fatigue, initial insomnia, reverse diurnal variation, poor ECT response, and adequate premorbid personality (West and Dally 1959). These patients appeared distinct from the endogenous and melancholic depressives, who were highly ECT responsive. Sargant (1961) also noted precipitating stress, irritability, tendency to blame others, weight loss, and difficulty in coping as features of this atypical depressive group.
Keywords
Panic Attack Atypical Depression Research Diagnostic Criterion British Medical Research Council Mood ReactivityPreview
Unable to display preview. Download preview PDF.
References
- British Medical Research Council, Clinical Psychiatric Committee (1965) Clinical trial of the treatment of depressive illness. Br Med J 1:881–886.CrossRefGoogle Scholar
- Greenblatt M, Grosser GH, Wechsler H (1964) Differential response of hospitalized depressed patients to somatic therapy. Am J Psychiatry 120:935–943.PubMedGoogle Scholar
- Klein DF, Davis J (1968) Diagnosis and drug treatment of psychiatric disorders, 1st edn. Williams & Wilkins, Baltimore.Google Scholar
- Klein DF, Gittelman R, Quitkin FM, Rifkin A (1980) Diagnosis and drug treatment of psychiatric disorders: adults and children, 2nd edn. Williams & Wilkins, Baltimore.Google Scholar
- Liebowitz MR, Klein DF (1979) Hysteroid dysphoria. Psychiatr Clin North Am 3:555–575.Google Scholar
- Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine vs imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 41:669–677.PubMedGoogle Scholar
- Liebowitz MR, Gorman JM, Fyer AJ, Klein DF (1985) Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry 42:729–736.PubMedGoogle Scholar
- Nies A, Howard D, Robinson DS (1982) Antianxiety effects of MAO inhibitors. In: Mathew RJ (ed) The biology of anxiety. Brunner/Mazel, New York.Google Scholar
- Paykel ES, Rowan PR, Parker RR, Bhat AV (1982) Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry 39:1041–1049.PubMedGoogle Scholar
- Ravaris CL, Nies A, Robinson DS, Ives JO, Lamborn KR, Korson L (1976) A multiple-dose controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 33:347–350.PubMedGoogle Scholar
- Ravaris CL, Robinson DS, Ivés JO, Nies A, Bartlett D (1980) Phenelzine and amitriptyline in the treatment of depression: a comparison of present and past studies. Arch Gen Psychiatry 37:1075–1080.PubMedGoogle Scholar
- Robinson DS, Nies A, Ravaris CL, Lamborn KR (1973) The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch Gen Psychiatry 29:407–413.PubMedGoogle Scholar
- Robinson DS, Nies A, Kayser A (1984) paper presented at ACNP, San Juan, Puerto Rico (December).Google Scholar
- Sargant W (1961) Drugs in the treatment of depression. Br Med J 1:225–227.PubMedCrossRefGoogle Scholar
- Sheehan DV, Ballenger J, Jacobson G (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37:51–59.PubMedGoogle Scholar
- Spitzer RL, Endicott J, Robins E (1978) Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 35:773–783.PubMedGoogle Scholar
- West ED, Dally PJ (1959) Effect of iproniazid in depressive syndroms. Br Med J 1:1491–1494.PubMedCrossRefGoogle Scholar